News Articles Tagged: ROS1-Positive NSCLC

Crizotinib as a Pharmaceutical Intermediate: Advancing Targeted Cancer Therapies

Explore the significance of Crizotinib as a pharmaceutical intermediate in creating targeted cancer therapies. NINGBO INNO PHARMCHEM CO.,LTD. highlights its properties and applications for ALK-positive and ROS1-positive cancers.

Understanding ROS1 Fusion-Positive NSCLC and the Role of Repotrectinib

Learn about ROS1 fusion-positive Non-Small Cell Lung Cancer (NSCLC) and how Repotrectinib, an advanced TKI, offers new hope. Discover the importance of its key intermediates for effective treatment.